More News

09 Jan 2017 Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds
09 Jan 2017 Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs
09 Jan 2017 Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
09 Jan 2017 Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus
09 Jan 2017 Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
09 Jan 2017 Mast Therapeutics And Savara Sign Merger Agreement
07 Jan 2017 Viriom Announces Collaboration with NIH on Zika and Other Major Viral Diseases
07 Jan 2017 HepaRegeniX GmbH Raises EUR9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
07 Jan 2017 Lin Bioscience Licenses First-in-Class Therapeutic Program to treat Dry Aged-Related Macular Degeneration from Columbia University in Collaboration with NIH
07 Jan 2017 SiteOne Therapeutics Announces Research and Development Agreement With Amgen to Advance Portfolio of Highly Selective, Potent Inhibitors of NaV1.7 for Acute and Chronic Pain
07 Jan 2017 BioAtla and F1 Oncology Announce Global Collaboration to Develop Adoptive Cellular Therapies for Solid Tumors
06 Jan 2017 OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement
06 Jan 2017 Cerveau Technologies, Inc. Signs License Agreement with Merck for Novel Investigational Tau Imaging Agent
06 Jan 2017 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
06 Jan 2017 Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
05 Jan 2017 Avidity Biosciences Raises $16 Million in Series B Financing to Advance Antibody-siRNA Conjugate Platform
05 Jan 2017 TOT BIOPHARM and LEE'S PHARM Signed an Exclusive Licensing Agreement on Monoclonal Antibody Drug TAB014
05 Jan 2017 Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology
05 Jan 2017 Synthetic Genomics Announces Collaboration with Johnson & Johnson Innovation to Develop Novel Therapeutics Using Synthetic Genomics' Replicon RNA Technology
05 Jan 2017 CiVi Biopharma Receives Worldwide Exclusive License to Develop a Novel, RNA Targeted Drug Against PCSK-9
05 Jan 2017 Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease
05 Jan 2017 Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
05 Jan 2017 NeRRe Therapeutics Raises £23 Million in Oversubscribed Series B Financing Round
05 Jan 2017 Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally
04 Jan 2017 Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing